BSE filing, NSE: LINCOLN. Summary written from the filing by ALFA Finder's alert engine.
Lincoln Pharmaceuticals Ltd: key numbers
- Share price
- ₹499.30
- Market cap
- ₹1,000 Cr
- Revenue (annual)
- ₹671.0 Cr
- Net profit (annual)
- ₹87.89 Cr
- P/E (TTM)
- 10.3×Sector 45.9×
- Promoter holding
- 49.78%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lincoln Pharmaceuticals Ltd
All →Lincoln Pharmaceuticals Q2 FY27 Results: Net Profit ₹20.4 Cr, Up 2.0% YoY
Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹191.3 Cr (+17.1% YoY) and net profit of ₹20.4 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.4 Cr · +2.0% YoY
Lincoln Pharmaceuticals Board Meeting Date
Lincoln Pharmaceuticals intimated that its Board meeting is scheduled for 29 Oct 2026 to approve Q1/H1 2026 financial results. Trading window remains closed until 48 hours after results are published.
Lincoln Pharmaceuticals Other Announcement
Lincoln Pharmaceuticals Ltd has filed its quarterly shareholding pattern statement for the period ended September 30, 2026, as required under SEBI regulations.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals Ltd announced the resignation of Mr. Pradeep Kumar Yadav, Senior General Manager - Quality Assurance, effective October 17, 2026.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals submitted the minutes and voting results of its 32nd Annual General Meeting held on September 30, 2026. The meeting concluded successfully.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals held its 32nd Annual General Meeting on September 30, 2026, where shareholders considered financial statements, dividends, and director reappointments.
Other debt & borrowing announcements
All →Neogen Chemicals Debt & Borrowing: ₹500 Cr
Neogen Chemicals approved in-principle a Rs 500 Crore corporate guarantee for Neogen Morita's borrowings, subject to shareholder approval. The company reports no adverse impact.
- Value
- ₹500.0 Cr
Satin Creditcare Network Debt & Borrowing: ₹1.83 Cr
Satin Creditcare paid Rs.1.83 Crore quarterly interest on its 10.40% April 2027 NCDs on 31 October 2026. The payment fulfils an existing debt obligation.
- Value
- ₹1.83 Cr
AAA Technologies Debt & Borrowing: ₹6 Cr
AAA Technologies approved an inter-corporate loan of up to Rs.6 Crore to Transaction Solutions International at 12% interest. Repayable on demand; share-pledge security is proposed.
- Value
- ₹6.00 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹12.5 Cr
Spandana Sphoorty partially redeemed Rs 12.50 Crore of its listed secured NCDs on 31 October 2026 by face-value redemption. Rs 200 Crore remains outstanding.
- Value
- ₹12.50 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹2.71 Cr
Spandana Sphoorty paid monthly interest of Rs 2.71 Crore across two listed secured NCD series on 30 October 2026, on time. Series-wise amounts were Rs 2.01 Crore and Rs 0.70 Crore.
- Value
- ₹2.71 Cr
Industrial Investment Trust Debt & Borrowing: ₹200 Cr
Industrial Investment Trust's board approved borrowing up to Rs. 200 Crore from banks, NBFCs and other lenders, within the Rs. 1,000 Crore shareholder limit. The enabling approval names no specific lender yet.
- Value
- ₹200.0 Cr